# EDGAR Filing Document

**Accession Number:** 0000846377
**File Stem:** 0001477932-26-001548
**Filing Date:** 2026-3
**Character Count:** 9974
**Document Hash:** 269971d27d55ad5a92f34f9c664d00a3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-001548.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001477932-26-001548

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260320

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Totaligent, Inc.
- **CENTRAL INDEX KEY:** 0000846377
- **STANDARD INDUSTRIAL CLASSIFICATION:** SHORT-TERM BUSINESS CREDIT INSTITUTIONS [6153]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 800142655
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55122
- **FILM NUMBER:** 26784936

**BUSINESS ADDRESS:**
- **STREET 1:** 2255 GLADES ROAD
- **STREET 2:** SUITE 324A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-988-2621

**MAIL ADDRESS:**
- **STREET 1:** 2255 GLADES ROAD
- **STREET 2:** SUITE 324A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLTEMP, INC.
- **DATE OF NAME CHANGE:** 20170428

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SOURCE FINANCIAL, INC.
- **DATE OF NAME CHANGE:** 20130225

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WIKI GROUP, INC.
- **DATE OF NAME CHANGE:** 20120316

?xml version='1.0' encoding='ASCII'? totaligent_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 20, 2026**

---

| |
|:---|
| **TOTALIGENT, INC.**  |
| **(Exact name of registrant as specified in its charter)**  |

---

---

| | | |
|:---|:---|:---|
| **Delaware**  | **001-41803** | **80-0142655** |
| (State or other <br>jurisdiction of incorporation)  | (Commission <br>File Number)  | (IRS Employer <br>Identification No.)  |

---

---

| | |
|:---|:---|
| **3651 FAU Boulevard, Suite 400**<br>**Boca Raton, Florida** | **33431** |
| (Address of principal executive offices)  | (Zip Code)  |

---

Registrant's telephone number, including area code: **<u>(561) 360-3565</u>**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12b of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange Registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 4, 2026, Totaligent, Inc. (the "Company") entered into an Extension Amendment (the "Amendment") to the Binding Letter of Intent dated February 11, 2026 (the "LOI") with Aetherium Medical ("Aetherium"). As previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2026, the LOI sets forth the principal terms for a proposed acqui-hire transaction pursuant to which the Company would acquire Aetherium's team, business plan, intellectual property, know-how, contacts, and related assets in exchange for equity in the Company.

The Amendment extends the target date for the negotiation and execution of definitive agreements (including, but not limited to, asset contribution agreements, intellectual property assignment agreements, employment or consulting agreements, and restricted stock agreements), and the target closing date of the transaction, from March 5, 2026, to April 10, 2026, to allow additional time for completion of negotiations and due diligence. The binding exclusivity period set forth in the LOI has been extended through April 10, 2026, or such earlier date as provided in the LOI, and is not affected by the Amendment. Except as expressly amended, all terms and conditions of the LOI remain in full force and effect.

The foregoing description is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [10.1](totaligent_ex101.htm) | [Extension Amendment to Binding Letter of Intent, dated March 20, 2026, between Totaligent, Inc. and Aetherium Medical.](totaligent_ex101.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TOTALIGENT, INC.** | **TOTALIGENT, INC.** |
| Date: March 24, 2026 | By:  | */s/ Edward C. DeFeudis* |
|  |  | Edward C. DeFeudis |
|  |  | CEO |

---

3<br>

## Exhibit 10.1

**EXHIBIT 10.1**

**Extension Amendment to Binding Letter of Intent**

This Extension Amendment (this "Amendment") to the Binding Letter of Intent dated February 11, 2026 (the "LOI"), is entered into as of March 20, 2026, by and between **Totaligent, Inc.**, a Delaware corporation with its principal place of business at 3651 FAU Boulevard, Suite 400, Boca Raton, Florida 33431 (the "Company"), and **Aetherium Medical**, with its principal executive officer Ivan Klarich (collectively with its team and assets, "Aetherium").

**Recitals**

WHEREAS, the Company and Aetherium entered into the LOI on February 11, 2026, pursuant to which the parties agreed to the principal terms of a proposed acqui-hire transaction, including the acquisition by the Company of Aetherium's team, business plan, intellectual property, know-how, contacts, and related assets in exchange for equity in the Company;

WHEREAS, the LOI provides that the parties intend to negotiate and execute definitive agreements (including, but not limited to, asset contribution agreements, intellectual property assignment agreements, employment or consulting agreements, and restricted stock agreements) within approximately four weeks from the date of the LOI, targeting a closing date of March 5, 2026;

WHEREAS, the parties have been unable to complete the negotiations for the definitive agreements by the targeted date due to ongoing due diligence and other preparatory matters;

WHEREAS, the parties desire to extend the target date for the execution of the definitive agreements and the closing of the transaction to April 10, 2026, to allow additional time for completion of negotiations;

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and in the LOI, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

**Agreement**

1. **Extension of Target Dates**. The LOI is hereby amended to extend the target date for the negotiation and execution of the definitive agreements, and the target closing date of the transaction, from March 5, 2026, to April 10, 2026. All references in the LOI to the target closing date or related timelines shall be deemed amended accordingly.

2. **Exclusivity Period**. The binding exclusivity period set forth in the LOI shall be extended through April 10, 2026, or such earlier date as provided in the LOI, and shall not be affected by this Amendment unless otherwise agreed in writing by the parties.

3. **No Other Changes**. Except as expressly amended herein, all terms and conditions of the LOI shall remain in full force and effect. In the event of any conflict between the terms of this Amendment and the LOI, the terms of this Amendment shall prevail.

4. **Binding Effect**. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

5. **Governing Law**. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of laws principles.

6. **Counterparts**. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart by electronic mail or other electronic means shall be effective as delivery of a manually executed counterpart.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

**TOTALIGENT, INC.**

---

| | |
|:---|:---|
| By: | */s/ Edward C. DeFeudis* |
| Name:  | Edward C. DeFeudis  |
| Title:  | CEO |

---

**AETHERIUM MEDICAL**

---

| | |
|:---|:---|
| By:  | */s/ Ivan Klarich* |
| Name:  | Ivan Klarich  |
| Title:  | Managing Director |

---